PL362437A1 - Diagnostyka i leczenie jaskry - Google Patents

Diagnostyka i leczenie jaskry

Info

Publication number
PL362437A1
PL362437A1 PL01362437A PL36243701A PL362437A1 PL 362437 A1 PL362437 A1 PL 362437A1 PL 01362437 A PL01362437 A PL 01362437A PL 36243701 A PL36243701 A PL 36243701A PL 362437 A1 PL362437 A1 PL 362437A1
Authority
PL
Poland
Prior art keywords
glaucoma
therapeutics
frp
diagnosing
diagnostics
Prior art date
Application number
PL01362437A
Other languages
English (en)
Other versions
PL208368B1 (pl
Inventor
Abbot F. Clark
John Fingert
Lorette Mcnatt
Edwin M. Stone
Wan-Heng Wang
Original Assignee
Alcon Laboratories, Inc.
University Of Iowa Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories, Inc., University Of Iowa Research Foundation filed Critical Alcon Laboratories, Inc.
Publication of PL362437A1 publication Critical patent/PL362437A1/pl
Publication of PL208368B1 publication Critical patent/PL208368B1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
PL362437A 2000-02-29 2001-02-26 Sposób diagnozowania jaskry PL208368B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18607300P 2000-02-29 2000-02-29

Publications (2)

Publication Number Publication Date
PL362437A1 true PL362437A1 (pl) 2004-11-02
PL208368B1 PL208368B1 (pl) 2011-04-29

Family

ID=22683545

Family Applications (1)

Application Number Title Priority Date Filing Date
PL362437A PL208368B1 (pl) 2000-02-29 2001-02-26 Sposób diagnozowania jaskry

Country Status (12)

Country Link
US (3) US7033755B2 (pl)
EP (2) EP1974738A3 (pl)
JP (2) JP2004512008A (pl)
KR (1) KR100748297B1 (pl)
CN (3) CN100460874C (pl)
AU (2) AU2001241768B2 (pl)
BR (1) BR0108802A (pl)
CA (2) CA2401775A1 (pl)
MX (1) MXPA02008487A (pl)
PL (1) PL208368B1 (pl)
WO (1) WO2001064949A2 (pl)
ZA (1) ZA200207647B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7704498A (en) * 1997-05-29 1998-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human frp and fragments thereof including methods for using them
US6600018B1 (en) * 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
CA2475690A1 (en) * 2002-03-01 2003-09-12 Flammer, Josef Diagnostic method for glaucoma
WO2004032838A2 (en) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
WO2004047757A2 (en) * 2002-11-21 2004-06-10 University Of Massachusets Diagnosing and treating hematopoietic cancers
WO2005111234A2 (en) * 2004-05-12 2005-11-24 Sugen, Inc. Methods of using zc1 and zc3 kinase substrate phosphorylation as biomarkers
CN1981054A (zh) * 2004-05-14 2007-06-13 加利福尼亚大学董事会 用抗wnt2单克隆抗体和sirna治疗癌症的方法
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
CN101128212A (zh) * 2005-01-18 2008-02-20 国立大学法人京都大学 用于神经细胞再生的药物
WO2006081379A1 (en) * 2005-01-26 2006-08-03 Wyeth Use of sfrps as markers of bmp activity
KR20080018858A (ko) * 2005-03-11 2008-02-28 알콘, 인코퍼레이티드 녹내장 치료용 플리즐 관련 단백질―１의 ＲＮＡⅰ－중재저해
US20060239951A1 (en) * 2005-03-30 2006-10-26 Alexandre Valentin Methods for stimulating hair growth by administering BMPs
WO2006116503A2 (en) * 2005-04-26 2006-11-02 Irm Llc Methods and compositions for modulating wnt signaling pathway
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
CN117379543A (zh) * 2017-08-20 2024-01-12 加州大学董事会 治疗青光眼的Wnt5a的调节
WO2021119188A1 (en) * 2019-12-09 2021-06-17 Sanofi Data processing systems and methods for repurposing drugs
JP7692581B2 (ja) * 2020-06-09 2025-06-16 株式会社島津製作所 眼疾患に関する評価方法
CN113405645B (zh) * 2021-06-08 2022-09-27 哈尔滨工程大学 一种基于活塞的耐静水压光纤水听器

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5235043B2 (pl) * 1973-01-24 1977-09-07
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4833080A (en) 1985-12-12 1989-05-23 President And Fellows Of Harvard College Regulation of eucaryotic gene expression
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5925748A (en) 1994-04-28 1999-07-20 The University Of Iowa Research Foundation DNA diagnostics for glaucoma
US5916778A (en) 1994-04-28 1999-06-29 University Of Iowa Research Foundation Diagnostics based on a glaucoma causing gene
US5885776A (en) 1997-01-30 1999-03-23 University Of Iowa Research Foundation Glaucoma compositions and therapeutic and diagnositic uses therefor
JP4063341B2 (ja) * 1994-07-06 2008-03-19 メイ株式会社 緑内障治療剤及び眼圧降下剤
US5789169A (en) * 1994-11-03 1998-08-04 Regents Of The University Of California Methods for the diagnosis of glaucoma
US5798380A (en) * 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
EP1019043A4 (en) * 1996-05-07 2003-07-30 Univ Pennsylvania INHIBITORS OF GLYCOGEN SYNTHESIS KINASE 3 AND METHOD FOR THEIR IDENTIFICATION AND USE
US5928662A (en) * 1996-07-31 1999-07-27 Phillips; Andrew F. Ocular drug delivery device
JP2001505434A (ja) * 1996-12-05 2001-04-24 クラーク，アボット，エフ． 緑内障の診断方法および抗緑内障薬の開発方法
JP2002504808A (ja) * 1997-03-24 2002-02-12 オニックス ファーマシューティカルズ，インコーポレイティド β−カテニン／転写因子相互作用に基づく病気を診断／治療するための組成物及び方法
WO1998044108A1 (en) * 1997-04-01 1998-10-08 The Regents Of The University Of California Diagnosis and prognosis of glaucoma
EP0879885A1 (en) * 1997-05-23 1998-11-25 Smithkline Beecham Corporation A novel human gene similar to a secreted murine protein sFRP-1
AU7704498A (en) * 1997-05-29 1998-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human frp and fragments thereof including methods for using them
CA2300390A1 (en) 1997-08-12 1999-02-25 Human Genome Sciences, Inc. Human frezzled-like protein
EP1054899A2 (de) * 1998-02-21 2000-11-29 Max-Delbrück-Centrum Für Molekulare Medizin Mittel zur therapie von menschlichen erkrankungen, ausgehend von beta-catenin, seine herstellung und seine verwendung
EP0943684A3 (en) * 1998-03-10 2002-01-23 Smithkline Beecham Plc Frizzled-like polypeptides and polynucleotides
JPH11292764A (ja) * 1998-04-07 1999-10-26 Mitsui Chem Inc グルタミン酸類が関与する疾患の治療および／または予防薬
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
IL148421A0 (en) 1999-09-13 2002-09-12 American Home Prod Pharmaceutical compositions and methods of using secreted frizzled related protein

Also Published As

Publication number Publication date
ZA200207647B (en) 2003-12-23
EP1259648A2 (en) 2002-11-27
WO2001064949A2 (en) 2001-09-07
WO2001064949B1 (en) 2002-12-05
WO2001064949A3 (en) 2002-09-19
CN100460874C (zh) 2009-02-11
US20020049177A1 (en) 2002-04-25
US7807355B2 (en) 2010-10-05
EP1974738A3 (en) 2008-12-17
CN1426482A (zh) 2003-06-25
CN101117644A (zh) 2008-02-06
AU2001241768B2 (en) 2006-04-27
MXPA02008487A (es) 2002-12-13
CA2729889A1 (en) 2001-09-07
EP1974738A2 (en) 2008-10-01
PL208368B1 (pl) 2011-04-29
AU4176801A (en) 2001-09-12
CN1196797C (zh) 2005-04-13
US7033755B2 (en) 2006-04-25
CN1667416A (zh) 2005-09-14
WO2001064949A9 (en) 2003-02-20
CA2401775A1 (en) 2001-09-07
JP2004512008A (ja) 2004-04-22
BR0108802A (pt) 2003-12-23
US20060216732A1 (en) 2006-09-28
KR20030005212A (ko) 2003-01-17
US20090226425A1 (en) 2009-09-10
KR100748297B1 (ko) 2007-08-09
JP2012025763A (ja) 2012-02-09

Similar Documents

Publication Publication Date Title
PL362437A1 (pl) Diagnostyka i leczenie jaskry
DE60239522D1 (de) Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
DE60207514D1 (de) Zusammensetzungen und Verfahren zum Nachweis und zur Behandlung von mit Chemokinrezeptoren verbundenen Krankheiten
WO2004113570A3 (en) Genotype test for dogs
Derks et al. Balancing selection for deleterious alleles in livestock
NZ334097A (en) Prolactin receptor gene as a genetic marker for increased litter size in pigs
EP1485504A4 (en) NEW HMGA ALLELES AND THEIR USE AS GENETIC MARKERS FOR GROWTH, BOLD, MEAT QUALITY AND FEED EFFICIENCY FEATURES
WO2005001032A3 (en) Fine mapping of chromosome 17 quantitative trait loci and use of same for marker assisted selection
CY1110138T1 (el) Προσδιορισμος υψηλης διεκπεραιωτικοτητας της δραστικοτητας lp-pla2
NO20074061L (no) DNA markorer for storfevekst
Dürig et al. A novel MITF variant in a white American Standardbred foal.
WO2006101623A3 (en) Cstf1 and c20orf43 markers for meat quality and growth rate in animals
WO2000024768A3 (en) Genes integrating signal transduction pathways
ATE499832T1 (de) Transgenes tiermodel für neurodegenerative krankheiten
EP1420637A4 (en) TRANSGENIC NOSES AS ANIMAL MODELS FOR THE MODULATION OF THE B1 BRADYKININ RECEPTOR PROTEIN
ATE406093T1 (de) Verfahren und zusammensetzungen für die pharmakologische und toxikologische auswertung von testsubstanzen
DE60200278D1 (de) Vorrichtung und Verfahren zur Beleuchtung des Melkstands
ATE473009T1 (de) Hemmung der neurodegeneration
WO2004071186A8 (en) Animal model for inflammatory bowel disease
DE602005024498D1 (de) Diagnostisches Verfahren zum Nachweis von der "Collie Eye Anomaly"
Sumreddee et al. 205 Runs of homozygosity and analysis of inbreeding depression
WO1999001577A1 (en) Reproductive and genetic screening samples of mutagenised animals
ATE417936T1 (de) Verfahren zur bestimmung des allelischen zustandes am 5'-ende des alpha-s1-kaseingens
ATE496531T1 (de) Verfahren zur identifizierung von kühen, zuchtbullen und zuchtstiermuttern die milch mit modifizierten coagulationseigenschaften erzeugen
WO2001057250A3 (en) Method for determining a predisposition of pigs to boar taint

Legal Events

Date Code Title Description
RECP Rectifications of patent specification